Key result
Frataxin overexpression protected cardiomyoblasts against doxorubicin-mediated mitochondrial iron accumulation, ROS formation, and cardiac hypertrophy.
Why the study?
Does frataxin overexpression prevent doxorubicin-mediated cardiac hypertrophy and mitochondrial dysfunction in preclinical models?
Population
Athymic mice and H9C2 cardiomyoblast cell lines
Design
Preclinical
Follow-up
2-week recovery (for mice)
Authors
Loading...
Supports frataxin-targeted approaches in doxorubicin cardiotoxicity models; hypothesis-generating and requires in vivo validation before clinical consideration.
Does frataxin overexpression prevent doxorubicin-mediated cardiac hypertrophy and mitochondrial dysfunction in preclinical models?
Frataxin plays a critical cardioprotective role against doxorubicin-mediated mitochondrial dysfunction and cardiac hypertrophy, offering novel insights into the pathogenesis of DOX-induced cardiomyopathy.
Mouli et al. (2015) studied Doxorubicin-mediated cardiac hypertrophy. Frataxin (FXN) overexpression was evaluated on Mitochondrial iron accumulation, ROS formation, and cardiac hypertrophy. Frataxin overexpression protected cardiomyoblasts against doxorubicin-mediated mitochondrial iron accumulation, ROS formation, and cardiac hypertrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: